
InMed Pharmaceuticals is a biotechnology business based in the US. InMed Pharmaceuticals shares (INM) are listed on the NASDAQ and all prices are listed in US Dollars. InMed Pharmaceuticals employs 13 staff and has a trailing 12-month revenue of around $1.4 million.
How to buy InMed Pharmaceuticals stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – INM. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
eToro
- Trade stocks and ETFs for $0 and no annual fee
- Minimum deposit of $10 required
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
Robinhood
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
InMed Pharmaceuticals stock price (NASDAQ: INM)
Use our graph to track the performance of INM stocks over time.InMed Pharmaceuticals shares at a glance
Latest market close | $2.08 |
---|---|
52-week range | $1.23 - $35.50 |
50-day moving average | $2.06 |
200-day moving average | $9.05 |
Wall St. target price | $20.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-1.17 |
Buy InMed Pharmaceuticals stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy InMed Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
InMed Pharmaceuticals price performance over time
Historical closes compared with the close of $2.08 from 2023-02-02
1 week (2023-01-27) | 15.56% |
---|---|
1 month (2023-01-03) | -5.88% |
3 months (2022-11-03) | -26.24% |
6 months (2022-08-03) | 420.00% |
1 year (2022-02-03) | 85.71% |
---|---|
2 years (2021-02-03) | -60.23% |
3 years (2020-01-30) | N/A |
5 years (2018-02-02) | 182.65% |
InMed Pharmaceuticals financials
Revenue TTM | $1.4 million |
---|---|
Gross profit TTM | $543,546 |
Return on assets TTM | -55.54% |
Return on equity TTM | -145.93% |
Profit margin | 0% |
Book value | $12.11 |
Market capitalisation | $3.3 million |
TTM: trailing 12 months
InMed Pharmaceuticals share dividends
We're not expecting InMed Pharmaceuticals to pay a dividend over the next 12 months.
You may also wish to consider:
- AbbVie (ABBV.US) (4.06% forward annual dividend yield)
Have InMed Pharmaceuticals's shares ever split?
InMed Pharmaceuticals's shares were split on a 1:25 basis on 7 September 2022. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your InMed Pharmaceuticals shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for InMed Pharmaceuticals shares which in turn could have impacted InMed Pharmaceuticals's share price.
InMed Pharmaceuticals share price volatility
Over the last 12 months, InMed Pharmaceuticals's shares have ranged in value from as little as $1.23 up to $35.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while InMed Pharmaceuticals's is 0.9812. This would suggest that InMed Pharmaceuticals's shares are less volatile than average (for this exchange).
To put InMed Pharmaceuticals's beta into context you can compare it against those of similar companies.
- Tilray (APHA.US): 2.6198
- Moderna (MRNA.US): 1.706
- Regeneron Pharmaceuticals (REGN.US): 0.2372
- AbbVie (ABBV.US): 0.624
InMed Pharmaceuticals overview
InMed Pharmaceuticals Inc. , a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa.
InMed Pharmaceuticals in the news
InMed Provides Business Update and Milestones for 2023
Frequently asked questions
What percentage of InMed Pharmaceuticals is owned by insiders or institutions?Currently 0.468% of InMed Pharmaceuticals shares are held by insiders and 20.964% by institutions. How many people work for InMed Pharmaceuticals?
Latest data suggests 13 work at InMed Pharmaceuticals. When does the fiscal year end for InMed Pharmaceuticals?
InMed Pharmaceuticals's fiscal year ends in June. Where is InMed Pharmaceuticals based?
InMed Pharmaceuticals's address is: 815 West Hastings Street, Vancouver, BC, Canada, V6C 1B4 What is InMed Pharmaceuticals's ISIN number?
InMed Pharmaceuticals's international securities identification number is: CA4576375022
More guides on Finder
-
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert